Form 8-K NEKTAR THERAPEUTICS For: Mar 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
March 1, 2016 4:55 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.40), $0.02 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $39.4 million versus the consensus estimate of $28.82 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More